業績

ページタイトル画像

論文業績 2021-2024

  • 2024
  • 2023
  • 2022
  • 2021

2024

  1. Muraosa Y, Hino Y, Takatsuka S, Watanabe A, Sakaida E, Saijo S, Miyazaki Y, Yamasaki S, Kamei K. Fungal chitin-binding glycoprotein induces Dectin-2-mediated allergic airway inflammation synergistically with chitin. PLoS Pathog. 2024 Jan 3;20(1):e1011878. doi: 10.1371/journal.ppat.1011878. PMID: 38170734; PMCID: PMC10763971.

  2. Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N. Correction to: Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Clin Exp Nephrol. 2024 Feb;28(2):123-124. doi: 10.1007/s10157-023-02436-9. Erratum for: Clin Exp Nephrol. 2024 Feb;28(2):85-122. doi: 10.1007/s10157-023-02415-0. PMID: 38070021; PMCID: PMC10808267.

  3. Matsui S, Ri C, Bolanos LC, Choi K, Shibamiya A, Ishii A, Takaishi K, Oshima-Hasegawa N, Tsukamoto S, Takeda Y, Mimura N, Yoshimi A, Yokote K, Starczynowski DT, Sakaida E, Muto T. Metabolic reprogramming regulated by TRAF6 contributes to the leukemia progression. Leukemia. 2024 May;38(5):1032-1045. doi: 10.1038/s41375-024-02245-3. Epub 2024 Apr 12. PMID: 38609495; PMCID: PMC11073974.

  4. Ishii A, Tsukamoto S, Mimura N, Miyamoto-Nagai Y, Isshiki Y, Matsui S, Nakao S, Shibamiya A, Hino Y, Kayamori K, Oshima-Hasegawa N, Muto T, Takeda Y, Suichi T, Misawa S, Ohwada C, Yokote K, Kuwabara S, Nakaseko C, Takamatsu H, Sakaida E. Detection of clonal plasma cells in POEMS syndrome using multiparameter flow cytometry. Sci Rep. 2024 May 6;14(1):10362. doi: 10.1038/s41598-024-61034-1. PMID: 38710832; PMCID: PMC11074311.

  5. Toya T, Mizuno K, Sakurai M, Kato J, Mori T, Doki N, Masuda S, Aotsuka N, Tsukamoto S, Sakaida E, Nakajima Y, Fujisawa S, Machida S, Aoyama Y, Yokoyama H, Shono K, Hatta Y, Usuki K, Kataoka K, Kanda Y. Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis. Blood Adv. 2024 Mar 12;8(5):1084-1093. doi: 10.1182/bloodadvances.2023010735. PMID: 38330190; PMCID: PMC10907401.

  6. Kawamura S, Tamaki M, Konuma T, Onizuka M, Sakaida E, Hayashi H, Doki N,
    Nishida T, Sawa M, Ohigashi H, Fukuda T, Ishikawa J, Matsuoka KI, Kawakita T, Tanaka M, Ishimaru F, Ichinohe T, Atsuta Y, Kanda Y, Yakushijin K, Kanda J, Nakasone H. Superiority of BM over PBSC for recipients with pre-transplant lung dysfunction in HLA-matched allogeneic HCT. Cytotherapy. 2024 Jun 12:S1465-3249(24)00757-6. doi: 10.1016/j.jcyt.2024.06.006. Epub ahead of print. PMID: 38958628.

  7. Ohwada C, Sakaida E, Takeda Y, Doki N, Igarashi A, Onizuka M, Toyosaki M, Tanaka M, Tachibana T, Kataoka K, Kato J, Fujisawa S, Kato S, Nakasone H, Naganuma K, Saitoh T, Shono K, Hagihara M, Saito T, Usuki K, Mori T, Nakaseko C, Okamoto S, Kanda Y. Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort. Int J Hematol. 2024 Sep;120(3):347-355. doi: 10.1007/s12185-024-03813-0. Epub 2024 Jul 17. PMID: 39017858.

  8. Matsumura I, Ohtake S, Atsuta Y, Kurata M, Minami Y, Takahashi N, Nakaseko C, Iriyama N, Fujimaki K, Kakihana K, Ogasawara Y, Ono T, Okada M, Tauchi T, Miyamoto T, Ohnishi K, Sakaida E, Fujisawa S, Kobayashi Y, Asou N, Naoe T, Kiyoi H, Miyazaki Y. Nilotinib vs. Dasatinib in Achieving MR4.5 for de novo Chronic Myeloid Leukemia: the Randomized JALSG CML212 Study. Blood Adv. 2024 Oct 22;8(20):5237-5247. doi: 10.1182/bloodadvances.2024012655. PMID: 38968156; PMCID: PMC11493191.

  9. Ureshino H, Takeda Y, Kamachi K, Ono T, Iriyama N, Ohtsuka E, Sakaida E, Kimura S. A Higher Neutrophil Count Is Associated with Favorable Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Received Second Generation Tyrosine Kinase Inhibitor as Frontline Treatment. Clin Pract. 2024 Jun 21;14(4):1216-1224. doi: 10.3390/clinpract14040097. PMID: 39051291; PMCID: PMC11270167.

  10. Shima M, Suzuki N, Nishikii H, Amano K, Ogawa Y, Kobayashi R, Ozaki R, Yoneyama K, Mizuno N, Sakaida E, Saito M, Okamura T, Ito T, Hattori N, Higasa S, Seki Y, Nogami K. Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Hemophilia A with or without Immunosuppressive Therapy. Thromb Haemost. 2024 Sep 12. doi: 10.1055/a-2384-3585. Epub ahead of print. PMID: 39134043.

  11. Nakao S, Tsukamoto S, Takeda Y, Ohwada C, Ri C, Izumi S, Kamata Y, Matsui S, Shibamiya A, Ishii A, Takaishi K, Takahashi K, Shiko Y, Oshima-Hasegawa N, Muto T, Mimura N, Yokote K, Nakaseko C, Sakaida E. Clinical impact of airflow obstruction after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2024 Oct;120(4):501-511. doi: 10.1007/s12185-024-03831-y. Epub 2024 Aug 27. PMID: 39190255; PMCID: PMC11415471.

  12. Seki Y, Ogawa Y, Kikuchi T, Sakaida E, Mizuta Y, Kitagawa T, Takemura K, Miyaguchi Y, Nogami K, Matsushita T. Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A. Int J Hematol. 2024 Oct;120(4):482-491. doi: 10.1007/s12185-024-03823-y. Epub 2024 Aug 19. PMID: 39158833; PMCID: PMC11415465.

  13. Kawamura S, Tamaki M, Konuma T, Onizuka M, Sakaida E, Hayashi H, Doki N, Nishida T, Sawa M, Ohigashi H, Fukuda T, Ishikawa J, Matsuoka KI, Kawakita T, Tanaka M, Ishimaru F, Ichinohe T, Atsuta Y, Kanda Y, Yakushijin K, Kanda J, Nakasone H. Superiority of BM over PBSC for recipients with pre-transplant lung dysfunction in HLA-matched allogeneic HCT. Cytotherapy. 2024 Nov;26(11):1353-1361. doi: 10.1016/j.jcyt.2024.06.006. Epub 2024 Jun 12. PMID: 38958628.

  14. Fujioka M, Itonaga H, Nakazawa H, Nishida T, Kataoka K, Ikeda T, Kako S, Matsuoka KI, Adachi K, Fujiwara SI, Aotsuka N, Kawakita T, Sakaida E, Kanda Y, Ichinohe T, Atsuta Y, Miyazaki Y, Ishiyama K. Superior Survival After Unrelated Allogeneic Stem Cell Transplantation With Low-Dose ATG Compared to Low-Dose TBI in Myeloablative Fludarabine/Busulfan-Based Regimen for MDS on Behalf of the Adult MDS Working Group of the JSTCT. Transplant Cell Ther. 2024 Oct 6:S2666-6367(24)00693-6. doi: 10.1016/j.jtct.2024.09.026. Epub ahead of print. PMID: 39374663.

  15. Shimizu H, Kato J, Tanoue S, Kimura SI, Tachibana T, Hatano K, Usuki K, Taguchi J, Hagihara M, Tsukada N, Harada K, Takahashi S, Takada S, Sakaida E, Fujisawa S, Onoda M, Aotsuka N, Handa H, Hatta Y, Nakaseko R, Yano S, Ohashi K, Kanda Y; Kanto Study Group for Cell Therapy (KSGCT). Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols. Leuk Res. 2024 Sep;144:107562. doi: 10.1016/j.leukres.2024.107562. Epub 2024 Aug 20. PMID: 39178610.

  16. Shimomura Y, Komukai S, Kitamura T, Tachibana T, Kurosawa S, Itonaga H, Tsukamoto S, Doki N, Katayama Y, Ito A, Sawa M, Ueda Y, Nakamae H, Nawa Y, Tanaka M, Arai Y, Ota S, Kataoka K, Nishida T, Kanda J, Fukuda T, Atsuta Y, Ishiyama K. The prognosis and risk factors for patients with complex karyotype myelodysplastic syndrome undergoing allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2024 Feb;204(2):612-622. doi: 10.1111/bjh.19139. Epub 2023 Oct 19. PMID: 37857379.

  17. Wakabayashi H, Hattori N, Uzawa A, Ito M, Hasegawa H, Mimura N, Empitu M, Aizawa M, Kuwabara S, Asanuma K, Oda S. Tryptophan-immunoadsorption plasmapheresis regulates polymorphonuclear-myeloid-derived suppressor cells and pro-inflammatory cytokines. Ther Apher Dial. 2024 Nov 7. doi: 10.1111/1744-9987.14228. Epub ahead of print. PMID: 39508126.

  18. Tomoyasu Jo, Kyoko Yoshihara, Masaki Ri, Nobuhiro Tsukada, Naoya Mimura, Keiko Fujii, Kentaro Fukushima, Shin-ichiro Fujiwara, Yuji Shimura, Kyoko Haraguchi, Koji Kato, Atsushi Satake, Akiyo Yoshida, Rikio Suzuki, Junko Ikemoto, Keita Iwaki, Wataru Takeda, Noboru Yonetani, Ryuji Tanosaki, Minami Yamada-Fujiwara, Kaoru Kahata, Tokiko Nagamura-Inoue, Satoshi Yoshihara, Yasuyuki Arai. Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR-T cell manufacturing failure in myeloma. Blood neoplasia. 100051. Oct 24, 2024.

 

 

和文論文

2024

  1. 瀬尾幸子, 河田英里, 入内島裕乃, 平尾磨樹, 吉原享子, 上田真寿, 半田寛, 中世古知昭, 伊藤薫樹, 飯田真介, 安倍正博, 堺田惠美子. ダイバーシティ推進委員会2023年度アンケート結果報告. 日本骨髄腫学会誌. 2024.

  2. 塩入勇翔. 塚本祥吉. 堺田惠美子. TAFRO症候群の診断と治療. EBM血液疾患の治療2025-2026(中外医学社)

2023

  1. Shima M, Amano K, Ogawa Y, Yoneyama K, Ozaki R, Kobayashi R, Sakaida E, Saito M, Okamura T, Ito T, Hattori N, Higasa S, Suzuki N, Seki Y, Nogami K. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost. 2023 Mar;21(3):534-545. doi: 10.1016/j.jtha.2022.10.004. Epub 2022 Dec 22. PMID: 36696195.

  2. Rizq O, Mimura N, Oshima M, Momose S, Takayama N, Itokawa N, Koide S, Shibamiya A, Miyamoto-Nagai Y, Rizk M, Nakajima-Takagi Y, Aoyama K, Wang C, Saraya A, Seimiya M, Watanabe M, Yamasaki S, Shibata T, Yamaguchi K, Furukawa Y, Chiba T, Sakaida E, Nakaseko C, Tamaru JI, Tai YT, Anderson KC, Honda H, Iwama A. UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease. Leukemia. 2023 Sep;37(9):1895-1907. doi: 10.1038/s41375-023-01928-7. Epub 2023 May 17. Erratum in: Leukemia. 2023 Sep;37(9):1952. doi: 10.1038/s41375-023-01969-y. PMID: 37198323; PMCID: PMC10457198.

  3. Shibamiya A, Miyamoto-Nagai Y, Koide S, Oshima M, Rizq O, Aoyama K, Nakajima-Takagi Y, Kato R, Kayamori K, Isshiki Y, Oshima-Hasegawa N, Muto T, Tsukamoto S, Takeda Y, Koyama-Nasu R, Chiba T, Honda H, Yokote K, Iwama A, Sakaida E, Mimura N. The pathogenetic significance of exhausted T cells in a mouse model of mature B cell neoplasms. Cancer Immunol Immunother. 2023 Aug;72(8):2635-2648. doi: 10.1007/s00262-023-03447-x. Epub 2023 Apr 17. PMID: 37069353; PMCID: PMC10992361.

  4.  Harada K, Onizuka M, Mori T, Shimizu H, Seo S, Aotsuka N, Takeda Y, Sekiya N, Kusuda M, Fujiwara S, Shiraiwa S, Shono K, Shingai N, Kanamori H, Momoki M, Takada S, Mukae J, Masuda S, Mitani K, Sakaida E, Tomikawa T, Takahashi S, Usuki K, Kanda Y. Prognostic factors for the development of lower respiratory tract infection after influenza virus infection in allogeneic hematopoietic stem cell transplantation recipients: A Kanto Study Group for Cell Therapy multicenter analysis. Int J Infect Dis. 2023 Jun;131:79-86. doi: 10.1016/j.ijid.2023.03.045. Epub 2023 Mar 29. PMID: 37001798.

  5. Jo T, Yoshihara S, Okuyama Y, Fujii K, Henzan T, Kahata K, Yamazaki R, Takeda W, Umezawa Y, Fukushima K, Ashida T, Yamada-Fujiwara M, Hanajiri R, Yonetani N, Tada Y, Shimura Y, Nishikii H, Shiba N, Mimura N, Ando J, Sato T, Nakashima Y, Ikemoto J, Iwaki K, Fujiwara SI, Ri M, Nagamura-Inoue T, Tanosaki R, Arai Y. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan. Br J Haematol. 2023 Apr 25. doi: 10.1111/bjh.18831. Epub ahead of print. PMID: 37096915.

  6. Qiang N, Ao J, Nakamura M, Chiba T, Kusakabe Y, Kaneko T, Kurosugi A, Kogure T, Ma Y, Zhang J, Ogawa K, Kan M, Iwanaga T, Sakuma T, Kanayama K, Kanzaki H, Kojima R, Nakagawa R, Kondo T, Nakamoto S, Muroyama R, Kato J, Mimura N, Ma A, Jin J, Kato N. Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma. Int Immunopharmacol. 2023 May;118:110068. doi: 10.1016/j.intimp.2023.110068. Epub 2023 Mar 29. PMID: 37001386.

  7. Iwanaga T, Chiba T, Nakamura M, Kaneko T, Ao J, Qiang N, Ma Y, Zhang J, Kogure T, Yumita S, Ishino T, Ogawa K, Kan M, Nakagawa M, Fujiwara K, Fujita N, Sakuma T, Kanzaki H, Koroki K, Kusakabe Y, Inoue M, Kobayashi K, Kanogawa N, Kiyono S, Kondo T, Nakagawa R, Ogasawara S, Nakamoto S, Muroyama R, Kato J, Kanda T, Maruyama H, Mimura N, Honda T, Murayama T, Nakamura H, Kato N. Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells. Biochem Biophys Res Commun. 2023 Jan 29;642:192-200. doi: 10.1016/j.bbrc.2022.12.025. Epub 2022 Dec 10. PMID: 36586187.

  8. Akahoshi Y, Tada Y, Sakaida E, Kusuda M, Doki N, Uchida N, Fukuda T, Tanaka M, Sawa M, Katayama Y, Matsuoka KI, Ozawa Y, Onizuka M, Kanda J, Kanda Y, Atsuta Y, Nakasone H. Novel risk assessment for the intensity of conditioning regimen in older patients. Blood Adv. 2023 Sep 12;7(17):4738-4747. doi: 10.1182/bloodadvances.2022008706. PMID: 36508283; PMCID: PMC10468368.

  9. Sato A, Kobayashi M, Yusa N, Ogawa M, Shimizu E, Kawamata T, Yokoyama K, Ota Y, Ichinohe T, Ohno H, Mori Y, Sakaida E, Kondo T, Imoto S, Nannya Y, Mitani K, Tojo A. Clinical and prognostic features of Langerhans cell histiocytosis in adults. Cancer Sci. 2023 Sep;114(9):3687-3697. doi: 10.1111/cas.15879. Epub 2023 Jun 26. PMID: 37364599; PMCID: PMC10475785.

  10. Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N. Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Clin Exp Nephrol. 2024 Feb;28(2):85-122. doi: 10.1007/s10157-023-02415-0. Epub 2023 Oct 25. Erratum in: Clin Exp Nephrol. 2023 Dec 9;: PMID: 37878114; PMCID: PMC10808569.

  11. Ando Y, Nishiyama H, Shimodaira H, Takano N, Sakaida E, Matsumoto K, Nakanishi K, Sakai H, Tsukamoto S, Komine K, Yasuda Y, Kato T, Fujiwara Y, Koyama T, Kitamura H, Kuwabara T, Yonezawa A, Okumura Y, Yakushijin K, Nozawa K, Goto H, Matsubara T, Hoshino J, Yanagita M; Committee of Clinical Practice Guidelines for the Management of Kidney Disease During Anticancer Drug Therapy 2022. Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol. 2023 Oct;28(10):1315-1332. doi: 10.1007/s10147-023-02382-2. Epub 2023 Jul 16. PMID: 37453935.

  12. Shimizu H, Najima Y, Kako S, Tanaka M, Fujiwara SI, Mori T, Usuki K, Gotoh M, Hagihara M, Tsukada N, Oniduka M, Takada S, Sakaida E, Fujisawa S, Onoda M, Aotsuka N, Yano S, Ohashi K, Takahashi S, Okamoto S, Kanda Y; Kanto Study Group for Cell Therapy (KSGCT). Clinical significance of late CMV disease in adult patients who underwent allogeneic stem cell transplant. J Infect Chemother. 2023 Dec;29(12):1103-1108. doi: 10.1016/j.jiac.2023.07.015. Epub 2023 Aug 1. PMID: 37532223.

  13. Rizq O, Mimura N, Oshima M, Momose S, Takayama N, Itokawa N, Koide S, Shibamiya A, Miyamoto-Nagai Y, Rizk M, Nakajima-Takagi Y, Aoyama K, Wang C, Saraya A, Ito R, Seimiya M, Watanabe M, Yamasaki S, Shibata T, Yamaguchi K, Furukawa Y, Chiba T, Sakaida E, Nakaseko C, Tamaru JI, Tai YT, Anderson KC, Honda H, Iwama A. Correction: UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease. Leukemia. 2023 Sep;37(9):1952. doi: 10.1038/s41375-023-01969-y. Erratum for: Leukemia. 2023 Sep;37(9):1895-1907. PMID: 37464071; PMCID: PMC10457190.

  14. Shimomura Y, Komukai S, Kitamura T, Tachibana T, Kurosawa S, Itonaga H, Tsukamoto S, Doki N, Katayama Y, Ito A, Sawa M, Ueda Y, Nakamae H, Nawa Y, Tanaka M, Arai Y, Ota S, Kataoka K, Nishida T, Kanda J, Fukuda T, Atsuta Y, Ishiyama K. The prognosis and risk factors for patients with complex karyotype myelodysplastic syndrome undergoing allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2023 Oct 19. doi: 10.1111/bjh.19139. Epub ahead of print. PMID: 37857379.

  15. Muto T, Walker CS, Agarwal P, Vick E, Sampson A, Choi K, Niederkorn M, Ishikawa C, Hueneman K, Varney M, Starczynowski DT. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation. Haematologica. 2023 Oct 1;108(10):2715-2729. doi: 10.3324/haematol.2022.282349. PMID: 37102608; PMCID: PMC10542836.

 

 

和文論文

2023

  1. 堺田惠美子.日本骨髄腫患者の会 『がんばりまっしょい』 2023年1月発刊 P12-27. 巻頭トピックス.「患者と医師で考える治療目標!ベクトルをあわせよう」

  2. 堺田惠美子. POEMS症候群の病態・診断・治療 2023年7月発刊 日本内科学会雑誌. 112 (7), 1223-1230.

  3. 加藤怜, 三村尚也. 『日本臨牀』月刊誌2023年6月 特集 多発性骨髄腫 update-診断・治療の最新動向- 「骨髄腫モデルマウス」. p863-868. 日本臨牀社

  4. 久保寺愛, 大島渚, 堺田惠美子. 『日本臨牀』月刊誌2023年6月 特集 多発性骨髄腫 update-診断・治療の最新動向-「POEMS症候群, Castleman病, TAFRO症候群の病態と治療の進歩」 p933-938. 日本臨牀社

  5. 城 友泰, 平安山 知子, 富澤 大輔, 吉原 哲, 加畑 馨, 藤原 実名美, 奥山 美樹, 柴 徳生, 藤井 敬子, 梅澤 佳央, 山﨑 理絵, 武田 航, 葉名尻 良, 福島 健太郎, 三村 尚也, 池本 純子, 岩木 啓太, 米谷 昇, 藤原 慎一郎, 李 政樹, 長村 登紀子, 田野﨑 隆二, 新井 康之. 急性リンパ性白血病に対するtisagenlecleucel製造結果—日本輸血・細胞治療学会CAR-T療法タスクフォースによる研究— 臨床血液. 2023;64(5):331-337.

  6. 一色 佑介, 大島 基彦, 三村 尚也, 堺田 惠美子, 岩間 厚志. Single-cell RNA sequencingを用いたPOEMS症候群における腫瘍細胞特異的な遺伝子発現および表面抗原パターンの発見. 臨床血液 2023;64(7):581-585.

  7. Muto T. [Role of innate immune signaling and inflammation in the pathogenesis of myeloid malignancies]. Rinsho Ketsueki. 2023;64(9):962-969. Japanese. doi: 10.11406/rinketsu.64.962. PMID: 37793872.

2022

  1. Yasuda T, Sanada M, Kawazu M, Kojima S, Tsuzuki S, Ueno H, Iwamoto E, Iijima-Yamashita Y, Yamada T, Kanamori T, Nishimura R, Kuwatsuka Y, Takada S, Tanaka M, Ota S, Dobashi N, Yamazaki E, Hirose A, Murayama T, Sumi M, Sato S, Tange N, Nakamura Y, Katsuoka Y, Sakaida E, Kawamata T, Iida H, Shiraishi Y, Nannya Y, Ogawa S, Taniwaki M, Asou N, Hatta Y, Kiyoi H, Matsumura I, Horibe K, Mano H, Naoe T, Miyazaki Y, Hayakawa F (2022) Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations. Blood 139 (12):1850-1862. doi:10.1182/blood.2021011921

  2. Utsunomiya A, Tokunaga M, Nakano N, Fujiwara H, Miyamoto T, Ogata M, Miyazaki Y, Ishitsuka K, Sakaida E, Taji H, Wakayama T, Ichinohe T, Fukuda T, Atsuta Y, Kato K, Yoshimitsu M (2022) Long-term follow-up of patients with ATL after autologous stem cell transplantation. Bone Marrow Transplant 57 (2):323-325. doi:10.1038/s41409-021-01412-9

  3. Utsumi A, Goto Y, Suzuki T, Imai C, Matsui S, Sakaida E, Ishii I (2022) Nelarabine-induced rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia: a case report. J Pharm Health Care Sci 8 (1):17. doi:10.1186/s40780-022-00247-w

  4. Takeshita K, Ishiwada N, Takeuchi N, Ohkusu M, Ohata M, Hino M, Hishiki H, Takeda Y, Sakaida E, Takahashi Y, Shimojo N, Hamada H. Immunogenicity and safety of routine 13-valent pneumococcal conjugate vaccination outside recommended age range in patients with hematological malignancies and solid tumors. Vaccine. 2022 Feb 23;40(9):1238-1245. doi: 10.1016/j.vaccine.2022.01.056. Epub 2022 Feb 4. PMID: 35125220.

  5. Takase Y, Tanioka S, Ishimura M, Yoshiura KI, Mori Y, Sakaida E, Funakoshi Y,
    Moriuchi H (2022) A familial case of B-cell expansion with NF-kappaB and T-cell anergy caused by a G123D heterozygous missense mutation in the CARD11 gene. Pediatr Blood Cancer 69 (12):e29941. doi:10.1002/pbc.29941

  6. Takahashi N, Cortes JE, Sakaida E, Ishizawa K, Ono T, Doki N, Matsumura I, García-Gutiérrez V, Rosti G, Ono C, Ohkura M, Tanetsugu Y, Viqueira A, Brümmendorf TH. Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis. Int J Hematol. 2022 Jun;115(6):838-851. doi: 10.1007/s12185-022-03314-y. Epub 2022 Mar 2. PMID: 35235189.

  7. Suichi T, Misawa S, Sekiguchi Y, Shibuya K, Nakamura K, Kano H, Aotsuka Y, Otani R, Morooka M, Tsukamoto S, Takeda Y, Mimura N, Ohwada C, Sakaida E, Kuwabara S (2022) Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. Intern Med 61 (17):2567-2572. doi:10.2169/internalmedicine.8786-21

  8. Sugawara M, Okada S, Kanda M, Iseki T, Sakaida E, Kobayashi Y (2022) Anagrelide-associated Cardiomyopathy and Heart Failure in a Patient with Essential Thrombocythemia: A Case Report and Literature Review. Intern Med 61 (21):3293-3299. doi:10.2169/internalmedicine.9090-21

  9. Shima M, Amano K, Ogawa Y, Yoneyama K, Ozaki R, Kobayashi R, Sakaida E, Saito M, Okamura T, Ito T, Hattori N, Higasa S, Suzuki N, Seki Y, Nogami K (2022) A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost. doi:10.1016/j.jtha.2022.10.004

  10. Ono T, Hino M, Matsumura I, Fujisawa S, Ishizawa K, Sakaida E, Sekiguchi N, Ono C, Aizawa M, Tanetsugu Y, Koide Y, Takahashi N (2022) Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study. Int J Hematol 116 (6):871-882. doi:10.1007/s12185-022-03435-4

  11. Ogawa K, Kanzaki H, Chiba T, Ao J, Qiang N, Ma Y, Zhang J, Yumita S, Ishino T, Unozawa H, Kan M, Iwanaga T, Nakagawa M, Fujiwara K, Fujita N, Sakuma T, Koroki K, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Ogasawara S, Suzuki E, Nakamoto S, Muroyama R, Kanda T, Maruyama H, Mimura N, Kato J, Motohashi S, Kato N (2022) Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience. J Cancer 13 (8):2656-2661. doi:10.7150/jca.71494

  12. Nakamae H, Yamamoto M, Sakaida E, Kanda Y, Ohmine K, Ono T, Matsumura I, Ishikawa M, Aoki M, Maki A, Shibayama H. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2022 Jan;115(1):33-42. doi: 10.1007/s12185-021-03216-5. Epub 2021 Sep 11. PMID: 34508295.

  13. Najima Y, Tachibana T, Takeda Y, Koda Y, Aoyama Y, Toya T, Igarashi A, Tanaka M, Sakaida E, Abe R, Onizuka M, Kobayashi T, Doki N, Ohashi K, Kanamori H, Ishizaki T, Yokota A, Morita S, Okamoto S, Kanda Y (2022) Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study. Ann Hematol 101 (12):2719-2729. doi:10.1007/s00277-022-04981-x

  14. Miyamoto-Nagai Y, Mimura N, Tsukada N, Aotsuka N, Ri M, Katsuoka Y, Wakayama T, Suzuki R, Harazaki Y, Matsumoto M, Kumagai K, Miyake T, Ozaki S, Shono K, Tanaka H, Shimura A, Kuroda Y, Sunami K, Suzuki K, Yamashita T, Shimizu K, Murakami H, Abe M, Nakaseko C, Sakaida E (2022) Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan. EJHaem 3 (3):838-848. doi:10.1002/jha2.534

  15. Konuma T, Harada K, Kondo T, Masuko M, Uchida N, Yano S, Kawakita T, Onizuka M, Ota S, Sakaida E, Miyakoshi S, Ozawa Y, Imamura Y, Kimura T, Kanda Y, Fukuda T, Atsuta Y, Yanada M, Adult Acute Myeloid Leukemia Working Group of the Japanese Society for T, Cellular T (2022) Salvage single-unit unrelated cord blood transplantation for graft failure following initial allogeneic transplantation in adult acute myeloid leukemia: trends in outcomes over the past 20 years. Bone Marrow Transplant 57 (12):1848-1850. doi:10.1038/s41409-022-01840-1

  16. Kato H, Maezawa Y, Nishijima D, Iwamoto E, Takeda J, Kanamori T, Yamaga M, Mishina T, Takeda Y, Izumi S, Hino Y, Nishi H, Ishiko J, Takeuchi M, Kaneko H, Koshizaka M, Mimura N, Kuzuya M, Sakaida E, Takemoto M, Shiraishi Y, Miyano S, Ogawa S, Iwama A, Sanada M, Yokote K (2022) A high prevalence of myeloid malignancies in progeria with Werner syndrome is associated with p53 insufficiency. Exp Hematol 109:11-17. doi:10.1016/j.exphem.2022.02.005

  17. Kameda K, Kako S, Kim SW, Usui Y, Kato K, Fukuda T, Uchida N, Kobayashi H, Wakayama T, Sakaida E, Yano S, Imada K, Nara M, Ikeda T, Fuchida SI, Ishikawa J, Sugahara H, Kanda J, Kimura T, Ichinohe T, Atsuta Y, Kondo E (2022) Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. Leukemia 36 (5):1361-1370. doi:10.1038/s41375-022-01545-w

  18. Kaito S, Kurosawa S, Najima Y, Sakaida E, Shingai N, Fukuda T, Tachibana T, Uchida N, Ozawa Y, Sawa M, Nakazawa H, Ota S, Kato J, Nakamae H, Katayama Y, Eto T, Tanaka J, Kanda Y, Atsuta Y, Arai Y, Kako S, Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell T (2022) Allogeneic Hematopoietic Stem Cell Transplantation for Adult Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Second Complete Remission. Transplant Cell Ther 28 (6):326 e321-326 e310. doi:10.1016/j.jtct.2022.03.017

  19. Isshiki Y, Oshima M, Mimura N, Kayamori K, Miyamoto-Nagai Y, Seki M, Nakajima-Takagi Y, Kanamori T, Iwamoto E, Muto T, Tsukamoto S, Takeda Y, Ohwada C, Misawa S, Ikeda JI, Sanada M, Kuwabara S, Suzuki Y, Sakaida E, Nakaseko C, Iwama A (2022) Unraveling unique features of plasma cell clones in POEMS syndrome with single-cell analysis. JCI Insight 7 (20). doi:10.1172/jci.insight.151482

  20. Muto T, Guillamot M, Yeung J, Fang J, Bennett J, Nadorp B, Lasry A, Redondo LZ, Choi K, Gong Y, Walker CS, Hueneman K, Bolanos LC, Barreyro L, Lee LH, Greis KD, Vasyliev N, Khodadadi-Jamayran A, Nudler E, Lujambio A, Lowe SW, Aifantis I, Starczynowski DT. TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity. Cell Stem Cell. 2022 Feb 3;29(2):298-314.e9.

  21. Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Tajika K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Kayamori K, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Kurosawa A, Mizoguchi A, Komatsu N, Fukuda T, Ohashi K, Kanda Y, Inokuchi K, Yamaguchi H. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv. 2022 Jan 11;6(1):238-247. doi: 10.1182/bloodadvances.2021004292. PMID: 34448807; PMCID: PMC8753195

  22. Akahoshi Y, Tada Y, Sakaida E, Kusuda M, Doki N, Uchida N, Fukuda T, Tanaka M, Sawa M, Katayama Y, Matsuoka KI, Ozawa Y, Onizuka M, Kanda J, Kanda Y, Atsuta Y, Nakasone H (2022) Novel risk assessment for the intensity of conditioning regimen in elderly patients. Blood Adv. doi:10.1182/bloodadvances.2022008706 

  

 

和文論文

2022

  1. 堺田惠美子. 『血液疾患 最新の治療 2023-2025』 巻頭トピックス-11  POEMS症候群. 2022年9月発刊

  2. 西原彩佳, 塚本祥吉, 堺田惠美子. 特集 「Onco-Nephrology (悪性腫瘍治療と腎機能障害)」 話題 抗がん剤・抗悪性腫瘍治療による腎機能障害 「造血幹細胞移植における腎障害:病態と対策」

  3. 堺田惠美子. 『今日の治療指針 2023年版』 アミロイドーシス.

  4. 堺田惠美子. 『日本医師会雑誌』 第151巻・特別号(1)(生涯教育シリーズ102)『血液疾患のすべて』 Ⅸ章. 多発性骨髄腫と類縁疾患 5. POEMS症候群

  5. 西原彩佳, 塚本祥吉, 堺田惠美子. 月刊『血液内科』 特集 「多発性骨髄腫および類縁疾患の病態解析と治療の進歩」 話題 POEMS症候群の病態解析と治療の進歩 第84巻第4号(2022年4月発刊) 84(4): 543-549, 2022

  6. 柴宮明日香, 三村尚也. 月刊『血液内科』 特集 「多発性骨髄腫および類縁疾患の病態と治療の進歩」 第84巻第4号(2022年4月発刊)

  7. 李 千尋, 三村尚也, 堺田惠美子. 月刊『血液内科』 特集「血液疾患における抗体医薬と免疫細胞療法の新たな展開」 びまん性大細胞型B細胞リンパ腫に対するCAR-T細胞療法の臨床効果. 第84巻第7号(2022年7月発刊)

  8. 三村尚也. 日本輸血・細胞治療学会 学会認定・アフェレーシスナース制度指定カリキュラム Ⅳ. 末梢血幹細胞採取  1.造血幹細胞とその動員(基礎)

  9. 中世古知昭, 大和田千桂子, 堺田惠美子.POEMS症候群. EBM血液疾患の治療2023-2024. (2022年10月発刊) 

  10. 石井改、塚本祥吉、堺田惠美子. マルチパラメーターフローサイトメトリーによる多発性骨髄腫およびPOEMS症候群クローンの検出 『血液内科』 第84巻 第5号. P1-6, 2(2022年5月発刊)

  11. 大和田千桂子, 堺田惠美子. 日本がん治療認定医機構. 教育セミナーテキスト. 第Ⅱ部 「白血病」第16版. P1-7

  12. 堺田惠美子. がん化学療法の薬-抗がん剤・ホルモン剤・分子標的薬・免疫チェックポイント阻害薬・支持療法薬-はや調べノート2023・2024年版 (YORi-SOU がんナーシング別冊) 単行本. 上野 誠 (監修), 古瀬 純司 (監修). P134-137. イブルチニブ, パノビノスタット, P226-227. チオテパ, P246-249. アクチノマイシンD、L-アスパラギナーゼ, P260-261, チラブルチニブ

  13. 西原彩佳, 塚本祥吉, 堺田惠美子. カレントテラピーVol :40 No 6. 見逃さない!潜んでいる血液疾患. 気づきのためのポイント集. 話題 POEMS症候群

  14. 堺田惠美子. 日本内科学会雑誌 第 111 巻第 7 号. VII.多発性骨髄腫の初期診断と外来治療 (2022年7月発刊)

  15. 堺田惠美子. インフォームドコンセントライブラリー. 目で見る慢性骨髄性白血病.カウンセリング・ブック (2022年5月改訂) 監修

  16. 三村尚也. 多発性骨髄腫情報誌がんばりまっしょい17号 「レポート 多発性骨髄腫研究助成」 多発性骨髄腫におけるT細胞疲弊の回復治療. 2022年3月

2021

  1. Yamashita M, Kuehn SH, Okuyama K, Okada S, Inoue Y, Mitsuiki N, Imai K, Takagi M, Kanegane H, Takeuchi M, Shimojo N, Tsumura M, Padhi AK, Zhang KYJ, Bertrand B, Casanova JL, Ohara O, Rosenzweig SD, Taniuchi I, Morio T. A Variant in Human AIOLOS Impairs Adaptive Immunity by Interfering with IKAROS. Nature Immunology volume 22, pages893–903 (2021)

  2. Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Miyazaki T, Aotsuka N, Gotoh M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter Analysis. Transplant Cell Ther. 2021 Jan;27(1):70.e1-70.e8. doi: 10.1016/j.bbmt.2020.09.025. Epub 2020 Sep 30. PMID: 33007494.

  3. Shibamiya A, Ohwada C, Ishii A, Mishina T, Nagai Y, Hino Y, Kayamori K, Oshima-Hasegawa N, Muto T, Tsukamoto S, Takeda Y, Mitsukawa S, Mimura N, Iseki T, Misawa S, Kuwabara S, Nakaseko C, Sakaida E. Successful second autologous stem-cell transplantation for patients with relapsed and refractory POEMS syndrome. Bone Marrow Transplant. 2021 Feb;56(2):517-520. doi: 10.1038/s41409-020-01024-9. Epub 2020 Aug 10. PMID: 32778687.

  4. Kikuchi T, Mori T, Ohwada C, Onoda M, Shimizu H, Yokoyama H, Onizuka M, Koda Y, Kato J, Takeda Y, Hino Y, Mishina T, Sakaida E, Shono K, Nagao Y, Yokota A, Matsumoto K, Morita K, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. Int J Hematol. 2021 Jan;113(1):128-133. doi: 10.1007/s12185-020-02990-y. Epub 2020 Sep 4. PMID: 32886279

  5. Nakasone H, Kako S, Mori T, Takahashi S, Onizuka M, Fujiwara SI, Sakura T, Sakaida E, Yokota A, Aotsuka N, Hagihara M, Tsukada N, Hatta Y, Usuki K, Watanabe R, Gotoh M, Fujisawa S, Yano S, Kanamori H, Okamoto S, Kanda Y. Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia. Bone Marrow Transplant. 2021 Jun;56(6):1402-1412. doi: 10.1038/s41409-020-01206-5. Epub 2021 Jan 8. PMID: 33420396.

  6. Nagai Y, Mimura N, Rizq O, Isshiki Y, Oshima M, Rizk M, Saraya A, Koide S, Nakajima-Takagi Y, Miyota M, Chiba T, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Nakaseko C, Lennox W, Sheedy J, Weetall M, Yokote K, Iwama A, Sakaida E. The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells. Sci Rep. 2021 Jan 22;11(1):2074. doi: 10.1038/s41598-021-81577-x. PMID: 33483574; PMCID: PMC7822878.

  7. Nakasone H, Kako S, Tachibana T, Tanaka M, Onizuka M, Takahashi S, Yokota A, Fujiwara SI, Sakura T, Sakaida E, Fujisawa S, Yamazaki R, Gotoh M, Hagihara M, Aotsuka N, Tsukada N, Hatta Y, Shimizu H, Usuki K, Watanabe R, Mori T, Yano S, Kanamori H, Kanda Y. Novel indicators of transplant outcomes for PhALL: "current molecular-relapse-free survival". Transplant Cell Ther. 2021 Jun 22:S2666-6367(21)01004-6. doi: 10.1016/j.jtct.2021.06.020. Epub ahead of print. PMID: 34171522.

  8. Kayamori K, Nagai Y, Zhong C, Kaito S, Shinoda D, Koide S, Kuribayashi W, Oshima M, Nakajima-Takagi Y, Yamashita M, Mimura N, Becker HJ, Izawa K, Yamazaki S, Iwano S, Miyawaki A, Ito R, Tohyama K, Lennox W, Sheedy J, Weetall M, Sakaida E, Yokote K, Iwama A. DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes. Blood Adv. 2021 Jan 26;5(2):438-450. doi: 10.1182/bloodadvances.2020001461. PMID: 33496740; PMCID: PMC7839369.

  9. Terakura S, Kuwatsuka Y, Sugita J, Takahashi S, Ozawa Y, Ozeki K, Yoshioka S, Nakamae H, Kawakita T, Sawa M, Morishige S, Najima Y, Katsuoka Y, Sakaida E, Kouzai Y, Kimura T, Ichinohe T, Fukuda T, Atsuta Y, Murata M, Teshima T. Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia. Int J Hematol. 2021 Jun;113(6):840-850. doi: 10.1007/s12185-021-03097-8. Epub 2021 Feb 21. PMID: 33611725.

  10. Kurosawa S, Kaito S, Uchida N, Fukuda T, Doki N, Mori T, Hasegawa Y, Takada S, Sakaida E, Tanaka M, Ikegame K, Kanda J, Atsuta Y, Kako S. Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia with high hyperdiploidy: a retrospective nationwide study. Leuk Lymphoma. 2021 Oct;62(10):2514-2520. doi: 10.1080/10428194.2021.1924374. Epub 2021 May 12. PMID: 33977832

  11. Yasuda S, Aoyama S, Yoshimoto R, Li H, Watanabe D, Akiyama H, Yamamoto K, Fujiwara T, Najima Y, Doki N, Sakaida E, Edahiro Y, Imai M, Araki M, Komatsu N, Miura O, Kawamata N. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations. Int J Hematol. 2021 Oct;114(4):424-440. doi: 10.1007/s12185-021-03180-0. Epub 2021 Jun 24. PMID: 34165774

  12. Shimazu Y, Mizuno S, Fuchida SI, Suzuki K, Tsukada N, Hanagaishi A, Itagaki M, Kataoka K, Kako S, Sakaida E, Yoshioka S, Iida S, Doki N, Oyake T, Ichinohe T, Kanda Y, Astuta Y, Takamatsu H; working group of the Japan Society for Transplantation, Cellular Therapy. Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine. Cancer Sci. 2021 Dec;112(12):5034-5045. doi: 10.1111/cas.15163. Epub 2021 Oct 26. PMID: 34644446

  13. Ishii A, Tsukamoto S, Mishina T, Izumi S, Nagai Y, Yamazaki M, Hino Y, Kayamori K, Oshima-Hasegawa N, Muto T, Mitsukawa S, Takeda Y, Mimura N, Ohwada C, Nakaseko C, Ikeda JI, Sakaida E. Successful allogeneic bone marrow transplantation after massive gastrointestinal bleeding in a patient with myelodysplastic syndrome associated with intestinal Behçet-like disease. Leuk Res Rep. 2021 Oct 29; 16:100278. doi: 10.1016/j.lrr.2021.100278. eCollection 2021. PMID: 34765438

  14. Hino Y, Watanabe A, Seki R, Tsukamoto S, Takeda Y, Sakaida E, Kamei K. A Reference Laboratory Surveillance on Fungal Isolates from Patients with Haematological Malignancy in Japan. J Fungi (Basel). 2021 Sep 27;7(10):806. doi: 10.3390/jof7100806. PMID: 34682228

  15. Ohwada C, Yamazaki S, Shono K, Kayamori K, Hino Y, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, Mimura N, Takeuchi M, Iseki T, Onoda M, Yokota A, Suzuki T, Ishii I, Nakaseko C, Sakaida E. Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation. Int J Hematol. 2021 Dec;114(6):664-673. doi: 10.1007/s12185-021-03188-6. Epub 2021 Sep 14. PMID: 34523110

  16. Kimura K, Tsukamoto S, Miyazaki K, Kawajiri-Manako C, Ishii A, Rahmutulla B, Fukuyo M, Oshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Takeuchi M, Ohwada C, Iseki T, Matsusaka K, Sanada M, Yokote K, Kaneda A, Ishida T, Suzuki K, Nakaseko C, Sakaida E. Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing. Exp Hematol. 2021 Sep;101-102:34-41.e4. doi: 10.1016/j.exphem.2021.08.001. Epub 2021 Aug 17. PMID: 34411686

  17. Mishina T, Oshima-Hasegawa N, Tsukamoto S, Fukuyo M, Kageyama H, Muto T, Mimura N, Rahmutulla B, Nagai Y, Kayamori K, Hino Y, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Tsujimura H, Iseki T, Nakaseko C, Ikeda JI, Itami M, Yokote K, Ohara O, Kaneda A, Sakaida E. Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort. Br J Haematol. 2021 Dec;195(5):731-742. doi: 10.1111/bjh.17765. Epub 2021 Aug 10. PMID: 34378195

  18. Yasuda T, Sanada M, Kawazu M, Kojima S, Tsuzuki S, Ueno H, Iwamoto E, Iijima-Yamashita Y, Yamada T, Kanamori T, Nishimura R, Kuwatsuka Y, Takada S, Tanaka M, Ota S, Dobashi N, Yamazaki E, Hirose A, Murayama T, Sumi M, Sato S, Tange N, Nakamura Y, Katsuoka Y, Sakaida E, Kawamata T, Iida H, Shiraishi Y, Nannya Y, Ogawa S, Taniwaki M, Asou N, Hatta Y, Kiyoi H, Matsumura I, Horibe K, Mano H, Naoe T, Miyazaki Y, Hayakawa F. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations. Blood. 2021 Oct 25: blood.2021011921. doi: 10.1182/blood.2021011921. Online ahead of print. PMID: 34695176

  19. Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura
    SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Miyazaki T, Aotsuka N, Gotoh M, Watanabe R, Shono K, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT).Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis. Ann Hematol. 2021 Nov;100(11):2763-2771. doi: 10.1007/s00277-021-04607-8. Epub 2021 Aug 6. PMID: 34357435

  20. Kusakabe Y, Chiba T, Oshima M, Koide S, Rizq O, Aoyama K, Ao J, Kaneko T, Kanzaki H, Kanayama K, Maeda T, Saito T, Nakagawa R, Kobayashi K, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Nakamoto S, Yasui S, Mikata R, Muroyama R, Kanda T, Maruyama H, Kato J, Mimura N, Ma A, Jin J, Zen Y, Otsuka M, Kaneda A, Iwama A, Kato N. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.Sci Rep. 2021 Nov 1;11(1):21396. doi: 10.1038/s41598-021-00889-0.PMID: 34725436

  21. Kanzaki H, Chiba T, Ao J, Koroki K, Kanayama K, Maruta S, Maeda T, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Ogasawara S, Suzuki E, Ooka Y, Muroyama R, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Mimura N, Kato J, Zen Y, Ohtsuka M, Iwama A, Kato N. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. Sci Rep. 2021 Mar 5;11(1):5303. doi: 10.1038/s41598-021-84117-9. PMID: 33674622

  22. Ao J, Chiba T, Shibata S, Kurosugi A, Qiang N, Ma Y, Kan M, Iwanaga T, Sakuma T, Kanzaki H, Kanayama K, Kojima R, Kusakabe Y, Nakamura M, Saito T, Nakagawa R, Kondo T, Ogasawara S, Suzuki E, Muroyama R, Kato J, Mimura N, Kanda T, Maruyama H, Kato N. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells.Biochem Biophys Res Commun. 2021 Apr 16;549:171-178. doi: 10.1016/j.bbrc.2021.02.097. Epub 2021 Mar 3. PMID: 33676186

 

 

和文論文

2021

  1. 堺田惠美子. 臨床血液, 日本血液学会 教育講演特別号. 初発慢性骨髄性白血病の治療戦略 Rinsho Ketsueki. 2021;62(8):1012-1023. doi: 10.11406/rinketsu.62.1012. PMID: 34497187

  2. 堺田惠美子. 専門医のための血液病学. [IV] 白血球系疾患 2.リンパ系 15) POEMS症候群 (医学書院)
     
  3. 石井改、塚本祥吉、堺田惠美子 『腫瘍内科』 7.ASH meeting report 2) 急性白血病

  4. 一色佑介、三村尚也、塚本祥吉、堺田惠美子、中世古知昭. 月刊『血液内科』 特集/血液内科医が注意すべき免疫異常・免疫不全. POEMS症候群に特徴的な免疫グロブリン軽鎖変異パターン. 第82巻第5号(2021年5月)
     
  5. 鎌田百合、大島 渚、堺田惠美子. POEMS症候群の診断と治療. 月刊「血液内科」 83巻第2号. P1-7. 2021年8月発刊

  6. 堺田惠美子. 悪性腫瘍の病態と治療 SBO 105 悪性腫瘍の治療における薬物治療の位置づけ. 日本薬学会スタンダード薬学シリーズ 総監修 市川厚 第6巻 薬と疾病 Ⅲ. 薬物治療(2)および薬物治療に役だつ情報 第3版 東京化学同人 2021年改訂

  7. 三村 尚也. 臨床血液. 多発性骨髄腫に対する新規エピジェネティック治療
     [Novel epigenetic therapies for multiple myeloma]. Rinsho Ketsueki. 2021;62(4):314-320. doi: 10.11406/rinketsu.62.314. PMID: 33967157

  8. 武藤朋也. 医学のあゆみ. 炎症性微小環境から迫る骨髄異形成症候群の病態. 2021; 277 (13), 1121–1122.